Φορτώνει......
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
PURPOSE: Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Ther |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497957/ https://ncbi.nlm.nih.gov/pubmed/25823918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.02.018 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|